Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 8(6): e65934, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23805193

RESUMO

BACKGROUND: Bacterial vectors have been proposed as novel vaccine strategies to induce strong cellular immunity. Attenuated strains of Brucella abortus comprise promising vector candidates since they have the potential to induce strong CD4(+) and CD8(+) T-cell mediated immune responses in the absence of excessive inflammation as observed with other Gram-negative bacteria. However, some Brucella strains interfere with the maturation of dendritic cells (DCs), which is essential for antigen-specific T-cell priming. In the present study, we investigated the interaction of human monocyte-derived DCs with the smooth attenuated B. abortus strain (S) 19, which has previously been employed successfully to vaccinate cattle. METHODOLOGY/PRINCIPAL FINDINGS: We first looked into the potential of S19 to hamper the cytokine-induced maturation of DCs; however, infected cells expressed CD25, CD40, CD80, and CD86 to a comparable extent as uninfected, cytokine-matured DCs. Furthermore, S19 activated DCs in the absence of exogeneous stimuli, enhanced the expression of HLA-ABC and HLA-DR, and was able to persist intracellularly without causing cytotoxicity. Thus, DCs provide a cellular niche for persisting brucellae in vivo as a permanent source of antigen. S19-infected DCs produced IL-12/23p40, IL-12p70, and IL-10, but not IL-23. While heat-killed bacteria also activated DCs, soluble mediators were not involved in S19-induced activation of human DCs. HEK 293 transfectants revealed cellular activation by S19 primarily through engagement of Toll-like receptor (TLR)2. CONCLUSIONS/SIGNIFICANCE: Thus, as an immunological prerequisite for vaccine efficacy, B. abortus S19 potently infects and potently activates (most likely via TLR2) human DCs to produce Th1-promoting cytokines.


Assuntos
Brucella abortus/fisiologia , Células Dendríticas/metabolismo , Interleucina-12/metabolismo , Antígeno B7-1/metabolismo , Antígenos CD40/metabolismo , Células Cultivadas , Citocinas/metabolismo , Células Dendríticas/citologia , Células Dendríticas/microbiologia , Células HEK293 , Antígenos HLA/metabolismo , Antígenos HLA-DR/metabolismo , Humanos , Interleucina-10/metabolismo , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Interleucina-23/metabolismo , Interleucina-8/metabolismo , NF-kappa B/metabolismo , Receptor 2 Toll-Like/genética , Receptor 2 Toll-Like/metabolismo
2.
J Dtsch Dermatol Ges ; 3(6): 421-30, 2005 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-15892844

RESUMO

Malignant melanoma is a primarily cutaneous melanocytic tumour with increasing incidence responsible for 90 % of skin cancer mortality. Genetic predisposition has been identified as the most important risk factor, while UV is second in importance and can be avoided. New diagnostic methods include sentinel lymph node biopsy and the detection of tumour markers in blood. Furthermore, malignant melanoma shows an extraordinary resistance to therapy; at present the only cure lies in early excision of the primary tumour. Thus early recognition is of utmost importance. Experimental approaches, such as dendritic cell vaccination, have shown some effectiveness which must be confirmed in multicenter, randomised trials.


Assuntos
Melanoma , Neoplasias Cutâneas , Adulto , Biomarcadores Tumorais , Vacinas Anticâncer/uso terapêutico , Criança , Células Dendríticas , Predisposição Genética para Doença , Humanos , Melanoma/diagnóstico , Melanoma/genética , Melanoma/mortalidade , Melanoma/patologia , Melanoma/prevenção & controle , Melanoma/cirurgia , Melanoma/terapia , Prognóstico , Risco , Fatores de Risco , Biópsia de Linfonodo Sentinela , Pele/patologia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/mortalidade , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/prevenção & controle , Neoplasias Cutâneas/cirurgia , Neoplasias Cutâneas/terapia , Fatores de Tempo , Raios Ultravioleta/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...